Articles by Silas Inman

Latest Articles

Rivaroxaban Approval Sought for Recurrent VTE Risk Reduction
  |  Silas Inman
A supplemental new drug application has been submitted to the US Food and Drug Administration (FDA) for 10-mg rivaroxaban as a treatment to reduce the risk of recurrent venous thromboembolism (VTE) after at least six months of standard anticoagulation therapy.
Republicans Release ACA Replacement
  |  Silas Inman
Republicans in the House of Representatives have proposed a replacement bill for the Affordable Care Act, which it hopes will pass Congress within the next 30 days.
FDA Approves Spiriva Respimat for Asthma in Children
  |  Silas Inman
The expanded indication was granted under the FDA's priority review program.
FDA Approves Brodalumab for Plaque Psoriasis
  |  Silas Inman
The FDA has approved brodalumab for moderate-to-severe plaque psoriasis in patients who are eligible for systemic therapy or phototherapy and who have failed to respond or stopped responding to other systemic therapies.
Trump Calls for 'Prompt Repeal' of ACA in First Executive Order
  |  Silas Inman
Just hours after taking the oath of office, President Donald J. Trump has already signed an executive order calling for the prompt repeal of the Affordable Care Act (ACA).
FDA Rejects Solithromycin for Bacterial Pneumonia
  |  Silas Inman
The FDA has issued a complete response letter for the oral and intravenous antibiotic solithromycin as a treatment for patients with community-acquired bacterial pneumonia, due to concerns over hepatotoxicity and manufacturing issues.
FDA Approves Adynovate for Hemophilia A in Pediatric and Surgical Settings
  |  Silas Inman
The FDA has approved Adynovate (PEGylated antihemophilic factor [recombinant]) as a treatment for hemophilia A in pediatric patients under 12 years of age and for both adults and pediatric patients in the surgical setting, based on findings from a phase 3 trial.
FDA Approves Nusinersen for Spinal Muscular Atrophy
  |  Silas Inman
The FDA has approved nusinersen as a treatment for children and adults with spinal muscular atrophy (SMA), an often fatal genetic disease affecting muscle strength and movement.
FDA Approves Synribo for CML
  |  Silas Inman
The FDA has approved omacetaxine mepesuccinate for the treatment of adult patients with Philadelphia chromosome-positive CML who have progressed after treatment with at least two prior TKIs.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$